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Abstract
Infection by human immunodeficiency virus (HIV) is associated with an early immune dysfunction
and progressive destruction of CD4+ T lymphocytes. This progressive disappearance of T cells leads
to a lack of immune control of HIV replication and to the development of immune deficiency resulting
in the increased occurrence of opportunistic infections associated with acquired immune deficiency
syndrome (AIDS). The HIV-induced, premature destruction of lymphocytes is associated with the
continuous production of HIV viral proteins that modulate apoptotic pathways. The viral proteins,
such as Tat, Env, and Nef, are associated with chronic immune activation and the continuous
induction of apoptotic factors. Viral protein expression predisposes lymphocytes, particularly
CD4+ T cells, CD8+ T cells, and antigen-presenting cells, to evolve into effectors of apoptosis and
as a result, to lead to the destruction of healthy, non-infected T cells. Tat and Nef, along with Vpu,
can also protect HIV-infected cells from apoptosis by increasing anti-apoptotic proteins and down-
regulating cell surface receptors recognized by immune system cells. This review will discuss the
validity of the apoptosis hypothesis in HIV disease and the potential mechanism(s) that HIV proteins
perform in the progressive T cell depletion observed in AIDS pathogenesis.
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Introduction
Human immunodeficiency virus (HIV), a member of the primate lentivirus family of
retroviruses, is the etiologic agent of AIDS. AIDS has become the major cause of death in
individuals 25 to 44 years of age in the United States.1 As of December 1999, 16.3 million
people have died worldwide since the first cases were identified in 1981 and the total number
of people living with HIV/AIDS is currently estimated at 35 million.1 At the present rate, HIV
is spreading faster in the human population than any infectious agent in the last 100 years.
HIV has become the most intensely studied infectious agent in history and the research
generated has contributed to our increased understanding to several other fields of biology
including virology, immunology, oncology, and cell biology. The primary receptor for these
viruses is CD4 which was identified early in the studies of HIV pathogenesis.2 CD4 is a
necessary, but not a sufficient component for HIV-1 entry and replication.3,4 Chemokine
receptors, in conjunction with CD4, mediate the efficient entry of HIV into cells5–9 and the
use of different chemokine receptors by HIV accounts for the distinct cell tropism associated
with various isolates.
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The viral replication cycle of HIV is highly regulated by viral gene products. The HIV-1
genome encodes the Gag, Pol, and Env structural proteins and two regulatory gene products,
Tat and Rev. In addition, there are a number of accessory proteins encoded in the HIV-1 genome
(Nef, Vif, Vpr, and Vpu) that are dispensable for in vitro replication but necessary to varying
degrees for pathogenesis. As common for all retro-viruses, attachment of the HIV virion to
specific receptors (CD4 and coreceptors) is followed by penetration of the core into the
cell.3,4 After entry, the single stranded RNA genome is converted into a double stranded DNA
molecule by the viral RNA-dependent DNA polymerase, reverse transcriptase (RT). The
proviral DNA form is transported to the nucleus and it integrates into host chromosomes, where
synthesis of viral RNA is initiated and regulated by both cellular and viral proteins (Tat and
Rev). Structural proteins (Gag-Pol and Env) are assembled and the viral genomic RNA is
encapsidated into the newly synthesized virion. Post budding and processing, the new virions
are released from the infected cell.
AIDS, T cell depletion, and the apoptosis hypothesis
HIV-1 infection results in the progressive destruction of CD4+ T lymphocytes. The pathogenic
importance of the loss of these T cells correlates with disease progression and increases
opportunistic infections, which subsequently leads to AIDS.10 The mechanisms of CD4+ T
cell depletion during HIV infection are incompletely understood, however, this depletion can
be mediated directly by HIV infection as a consequence of viral gene expression or indirectly
through priming for apoptosis of uninfected ‘bystander’ cells.10
The mechanism of T cell-induced death involves the complimentary proteins Fas, also known
as CD95 or Apo-1 and Fas ligand (Fas-L).11–14 The ligation of Fas/Fas-L is the main
mechanism for maintaining the appropriate number of T cells in the body. Therefore, this
apoptotic pathway has been hypothesized to enhance HIV-1 expression in infected patients
and subsequently to disrupt T cell homeostasis that eventually leads to the depletion of
CD4+ T lymphocytes. Several lines of evidence support this hypothesis. First, the proportion
of Fas expressing T cells in HIV-1-infected individuals increase with disease
progression.15,16 Second, Fas-L message can be detected in freshly isolated HIV-infected T
cells.17 Third, therapies with anti-Fas antibody and soluble Fas-L induce T cells to undergo
apoptosis.18 In addition, induction of Fas message in peripheral blood lymphocytes (PBL),
particularly in T cells and monocytes, from uninfected people can be upregulated when
cocultured with HIV infected cells.19 The significance of this last finding in terms of HIV-1
pathogenesis is unclear and has remained controversial. Other researchers have generated data
to indicate that Fas-dependent activation does not induce T cell death in HIV-1-infected
patients.20,21
This hypothesis, that apoptosis is important for HIV pathogenesis, has been proposed by several
researchers.22–26 A better understanding of HIV-mediated apoptosis is critical for the
development of anti-retroviral therapies and vaccines. In this review, we will discuss the
importance of apoptosis in HIV-1 disease and the role that HIV viral proteins contribute to the
regulation of apoptosis.
Endogenous and exogenous regulators of apoptosis
Apoptosis is an ordered, suicide mechanism that is characterized by cell shrinkage, loss of
membrane integrity, chromosomal condensation, and internucleosomal cleavage of DNA.
These changes are associated with the activation of cellular nucleases resulting in the
fragmentation of DNA into a ladder of regular nucleosomal subunits.27 It is now widely
appreciated that apoptosis contributes to most types of physiological cell death. However, its
participation in the pathological forms of cell death by HIV and other viruses is less fully
understood and might vary depending on the particular pathological agent.
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Studies analyzing the mechanisms responsible for apoptosis in human cells have revealed that
the cysteinyl aspartate-specific protease (caspase) family constitutes the effector arm of
apoptosis.28–31 Caspases are synthesized as inactive proenzymes that are activated by upstream
proteins in response to an apoptotic stimulus and are characterized by a cysteine located within
their active site.32 Following activation, caspases recognize specific sequences within their
various target proteins and characteristically cleave these proteins 3? of an aspartic acid residue
within the recognition sequence.33 Thus far, the 13 caspases identified differ with regard to
the activation stimuli and to their substrate specificity and sensitivity to various
inhibitors.34,35 In addition to caspases, other apoptosis-inducing proteases can be activated in
response to certain stimuli. One of these proteases, calpain, is a member of the calcium-
dependent cysteine proteases and is involved in some forms of apoptosis.36 Calpain substrates
are primarily calmodulin-binding proteins.36
The idea that apoptosis could be used by the host immune system as a defense against viruses
has been recognized for many years. A major line of defense against viral infections are
cytotoxic T cells (CTL), which can recognize and induce apoptosis in virally infected
cells.37 CTL use more than one killing pathway: (1) CTL express the ligand for Fas and thus
can kill Fas-bearing target cells; and (2) CTL bear granules that they can deliver into their
target cells. One of the proteases in these CTL granules, granzyme B, cleaves after aspartate
residues and activates many members of the caspase family.37–40
There are several proteins encoded by human cells and viruses that share structural similarities
and can both promote (Bax, Bak, Bok) and inhibit (Bcl-2, Bcl-x) apoptosis.40–45 These proteins
are members of the bcl-2 gene family and share sequence and functional homology to Ced-9
of Caenorhabditis elegans.46 The extensively studied Bcl-2 gene product is a major anti-
apoptotic regulator and therefore, Bcl-2 itself is highly regulated. Cell-type specific expression
of Bcl-2 and its interactions with the apoptotic protagonists, Bax and Bak are two major
regulatory mechanisms of this protein.47 Several members of this family dimerize via the Bcl-2
homology (BH) domain. Different sets of dimers either inhibit apoptosis (such as Bcl-2/Bax
heterodimers) or induce apoptosis (such as Bax homodimers). The Bcl-2 member proteins that
promote cell survival inhibit apoptosis upstream of caspase activation.47,48
A large number of viruses have evolved to encode specific inhibitors of caspase activation and
apoptosis. Cytokine response modifier A (CrmA) from cowpox virus is similar to the serpin
family of proteins and is able to inhibit caspase activation. CrmA acts as a substrate for
caspase-1 and interferes with the host immune response to the virus.49 The viral protein p35
(encoded by baculovirus) is a broad-spectrum inhibitor of apoptosis by acting as a substrate
for several caspases.50–52 To date, p35 blocks the induction of apoptosis by all stimuli
tested.51,52 Mutation of these genes allows for host cells to respond to infection by undergoing
apoptosis that in turn drastically reduces viral spread. A number of adenoviruses encode the
protein, E1B, which has similar properties to Bcl-2 by blocking apoptosis and interacting with
Bak and Bax.
However, not all data support the important role of Bcl-2 or Fas/Fas-L interaction in HIV-1-
induced disease. A recent study showed that during HIV-1 infection of T cells, E1B of
adenovirus and Bcl-2 only marginally decreased overall cell death.53 In addition, inhibition of
Fas/Fas-L interaction did not prevent HIV-induced cell death.53 Therefore, a non-apoptotic
pathway may serve as a major pathway of HIV-induced cell death.
Modulation of apoptosis by HIV infection
Primate retroviruses such as HIV-1, HIV-2, simian immunodeficiency virus (SIV), and human
T cell leukemia virus (HTLV), have considerably smaller genomes compared to other viruses
(herpesviruses, poxviruses, and baculoviruses) that encode genes for the regulation of
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apoptosis. Nevertheless, cells infected with HIV have a prolonged survival time initiated by a
variety of mechanisms including the modulation of Bcl-2, Fas, Fas-L, tumor necrosis factor ?
(TNF?) and caspase expression (Table 1).54 HIV-1 is therefore not unique among viruses in
regard to its ability to regulate apoptosis. HIV integrates into the host genome as part of its life
cycle and, in general, integrated viruses that constitutively express viral gene products serve
as good targets for the cellular immune response.3,4 HIV-induced apoptosis may therefore play
an important role in the viral life cycle by limiting the host immune response to virus infection
and thus facilitating viral persistence.55 HIV infection has been reported to abnormally activate
T cells and change the balance between T helper (Th)-1 and Th2 cells, possibly by increasing
apoptosis and decreasing CD4+ T cells.56 The modulation of apoptosis in HIV-infected and
uninfected cells is complex. Figure 1 describes the overall integrated effect of various HIV
gene products on apoptosis. Several viral proteins have been shown to effect apoptosis
including Tat, Env, Nef, Vpr and Vpu (Table 1). The following sections address the specific
actions of each of these proteins on the induction or inhibition of apoptosis in HIV-1
pathogenesis.
Tat
Tat is expressed early after HIV infection and stimulates viral gene expression by interacting
with the TAR element found in HIV mRNA.57,58 Tat has been associated with several
intracellular and extracellular proteins which suggests that Tat is capable of modulating various
biological effects.58 A soluble form of Tat (sTat) has been detected in HIV-1-infected patients
and in the supernatant of Tat transfected cells, which can be taken up by neighboring cells.59
Several reports indicate that Tat may effect B lymphocyte differentiation, growth of Kaposi
sarcomas, the down-regulation of MHC class I and the induction and protection from
apoptosis.60–65 Even though the role of direct cell killing of CD4+ T cells is a credible
hypothesis for the T cell depletion seen in AIDS patients,10 apoptosis is rarely observed in
HIV-1-infected cells. Co-culture experiments indicate that while uninfected T cells die by
apoptosis, HIV-infected cells remain resistant and this resistance has been partially mapped to
tat.55,66 Therefore, a dual role for Tat in regulation of apoptosis has been suggested: (1) Tat
induces apoptosis of HIV uninfected cells via exogenous sTat by sensitizing bystander cells
to Fas-mediated apoptosis; and (2) protecting HIV-infected cells from death by up-regulating
T cell growth factors and anti-apoptotic proteins.55
Support for the ‘bystander’-induced apoptosis theory is supported by experiments examining
the lymph nodes of SIV-infected macaques.55 Apoptosis occurs in the lymph nodes of these
animals primarily in neighboring, uninfected cells and not in the productively infected T
cells.54 Exogenous sTat interacts with cell surface receptors, possibly CD26 and integrin
?5?1, both of which can transduce signals leading to the down-regulation of Bcl-2 and induce
apoptosis.60,67,68 Tat induces Fas/Fas-L-dependent activation of apoptosis in T cell death.
These findings indicate that Tat, by initiating signals in T cells, either directly or indirectly
induces apoptosis in uninfected cells.67 The Tat-induced signaling pathway has yet to be
elucidated, but may involve the activation of inositol triphosphate (IP3)-phospholipase C
(PLC) pathway.69 Several proteins, including p56lck, CD45, and hematopoietic cell
phosphatase (HCP) as well as the transcription factors NF-?B and SP-1, have also been
implicated in Tat-mediated apoptosis.62
In contrast to sTat, endogenous Tat appears to protect T lymphocytes from apoptosis. However,
the mechanism for this protection remains unknown. In vitro studies indicate that cells
transfected with Tat expression plasmids were resistant to apoptosis.55 Endogenous Tat may
block apoptosis by up-regulation of IL-2 or the anti-apoptotic proteins bcl-2/bcl-x.70
Interestingly, endogenous Tat protects cells from exogenous sTat-induced apoptosis.
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Tat can have pronounced immunosuppressive affects. In mice transfected with Tat expression
vectors and in seroconverted infected humans, Tat expression cripples the immune surveillance
of the infected host.62–65,71–74 This immunosuppression affects both T cells and macrophages
and can be reversed with Fas/Fas-L antagonists.74 These observations have immediate
relevance to HIV vaccine development. Several vaccine approaches for limiting HIV infection
are currently underway and many include a Tat component in the vaccine. Vaccines in clinical
and pre-clinical trials have included: (1) Tat expression vectors (both soluble and endogenous
forms of Tat);75,76 (2) as part of a multiple DNA expression plasmids encoding for several
HIV genes;77 (3) in live attenuated HIV vaccines;78–83 and (4) in virus-like particles (VLPs)
both in DNA expression vectors and as purified protein.84 Therefore, a better comprehension
of Tat-induced apoptosis and immunosuppressive mechanisms are important for new vaccine
designs.85 Interestingly, a recent study demonstrated that an oxidized, inactivated form of Tat
does not produce the immunosuppressive effects associated with Tat and has been proposed
for vaccinations.86
Vpr
The 96 amino acid, 14 kDa accessory protein Vpr is highly conserved in HIV-1, HIV-2, and
SIV and confers rapid growth advantage to viruses expressing this gene product.87,88 Viruses
expressing Vpr have faster growth rates than Vpr-deficient viruses. Also, the effects of Vpr
are cell-type specific. Vpr augments the growth of HIV in macrophages, but does not enhance
viral growth in primary T cells.89 Vpr associates with the viral particle through the p6 molecule
of Gag90–92 and deletions or truncations of p6 prevent Vpr incorporation into the virion.93 The
incorporation of Vpr into progeny virions suggests that this protein participates in the early
events of viral infection. Several functional roles have been demonstrated for Vpr during HIV
replication. One of the more defined functions of Vpr is the nuclear translocation of the
preintegration complex.91,94–96 Vpr may enhance virus-specific functions such as reverse
transcriptase by either stabilizing the RNA–DNA or DNA–DNA molecules, migration of the
proviral DNA complex to the nucleus, or integration.97 It has been shown that Vpr, along with
the matrix p17 protein, acts to ensure the efficient nuclear import of the preintegration complex
in non-dividing cells such as macrophages.87
Besides the role in nuclear translocation, in vitro functions have been described for Vpr
including the enhancement of viral gene transcription.92 Vpr is localized primarily in the
nucleus. In dividing cells, Vpr has been shown to modestly trans-activate the HIV long terminal
repeat (LTR) and heterologous viral promoters.87,98 The exact mechanism by which Vpr
increases protein synthesis is not clear,99 however, it may be achieved by direct binding of Vpr
to the transcription factors TFIIB and Sp1.99,100
In proliferating T cells and stimulated peripheral blood mononuclear cells (PBMCs), Vpr
appears to be dispensable for the in vitro replication of HIV.101–107 However, under certain
conditions, Vpr contributes substantially to HIV-1 replication in these cells.99 Vpr has been
shown to induce cell cycle arrest of cells in the G2 phase of the cell cycle.103,104,108,109 The
Cdc2 kinase is an inactive form in G2-arrested cells. Recent reports suggest that Vpr disrupts
the regulation of Cdc2 kinase, which leads to G2 arrest.104,105,109 Vpr interacts with highly
conserved components of the cell cycle regulation pathways. Interestingly, others have reported
that Vpr specifically binds to the highly conserved DNA repair enzyme uracil DNA glycoslyase
(UNG), that is involved in removing uracil from DNA. However, the role of UNG-Vpr
interactions and cell cycle arrest is unclear.110–112
The different Vpr functions have been attributed to different regions of the protein.88,91 The
amino terminus is involved in virion incorporation and the nuclear location of the protein. The
carboxyl terminus of the protein is required to induce G2 arrest. Analysis of Vpr point mutants
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demonstrates a correlation between the extent of G2 arrest and the levels of apoptosis.106
Mutants that cause more cells to accumulate in G2 phase of the cell cycle show increased levels
of apoptosis.109 However, Vpr-induced apoptosis does not require maintenance of G2 arrest.
Studies by Stewart et al, indicate that treatment of Vpr-arrested cells with methlyxanthine
pentoxifyllin alleviates G2 arrest but does not reduce the levels of apoptosis.106 The Cdc2
kinase remained hyperphosphorylated during apoptosis, indicating that Cdc2 kinase was not
required for activation of the apoptotic pathways induced by Vpr.
In contrast, reports by Bartz et al104 show that Vpr induces cytostasis but not apoptosis.
Infection of Jurkat T cells with virions expressing Vpr resulted in G2 arrest but not
apoptosis.104 These infected cells continued to accumulate at G2 over a 72 h period, however,
no significant cell death was observed compared to Vpr mutant virions. The discrepancy
between these two studies is mostly likely due to the post-infection time point at which the
cells were monitored. Specifically, Bartz et al, monitored infected cells for only 3 days, whereas
Stewart et al, observed that apoptosis increased over time and was usually maximal 4 days
post-infection. Vpr increases apoptosis without addition of a second stimulus and Vpr-induced
apoptosis has been shown to be independent of Cdc2 kinase activity.106 Therefore, Vpr may
contribute to the overall induction of cell death and contribute to CD4+ T cell decline in disease
via G2 arrest and subsequent induction of apoptosis.
Env
Although the identification of specific coreceptors for HIV-1 infection represented an
important step forward in our understanding of HIV-1 pathogenesis, information about how
these receptors participate in the HIV replication cycle is just beginning to be understood. HIV
infection requires binding of the gp120 subunit of Env to both CD4 receptor and one of a variety
of chemokine receptors.3,113 The chemokine receptor CXCR4 is required for entry of T-tropic
isolates of HIV (named X4 strains) and CCR5 was determined to be the major coreceptor for
M-tropic strains of HIV (R5 strains).5–9,113 Even though these receptors are necessary for entry
of HIV into cells, the importance of Env interaction with these receptors, resulting in signal
transduction, is not totally understood. Activation of chemokine receptors by their cognate
ligands or Env proteins results in prominent changes in cell migration and cell growth by
stimulating various signal transduction pathways. Recent studies indicate that ?-chemokines
(which bind to CCR5) may exert indirect selective pressure in vivo in favor of the replication
of X4 isolates that do not require CCR5 for entry.114 Interestingly, this effect is evident only
at low inoculum of HIV.114 ?-chemokine-mediated enhancement of X4 HIV replication can
be detected at the early stages of HIV replication cycle and is dependent on signaling through
G proteins. These findings provide insight regarding signals, generated from HIV Env
receptors, which can enhance viral replication, possibly including signals that activate
apoptosis. In that regard, Env from X4 strains of HIV can induce apoptosis in vitro in CD8+
T cells and neuronal cells.115,116 The signaling pathway induced by Env/CXCR4 interaction
is complex, involving cross-talk with macrophages, and operates through the tumor-necrosis
factor-? (TNF-?) receptor II (TNFRII).114 Signaling by CXCR4 induces the surface expression
of TNF-? in macrophages and TNFRII in CD8+ T cells.117–119 Subsequently, contact between
the macrophages and T cells triggers T cell death. Although a low percentage of CD8+ T cells
were apoptotic in these studies, the loss of viable cells was high. Interestingly, this Env-induced
death of CD8+ T cells through CXCR4 and TNF-?/TNFRII signaling resembles the Env-
induced death of CD4+ T cells through CD4 and Fas/Fas-L receptor signaling.119 TNF-?/
TNFRII and Fas/Fas-L belong to the same apoptosis-transducing pathway, which are involved
in the physiological control of T cells.120 Therefore, X4-Envs may induce premature cell death
in both CD4+ and CD8+ T cell populations through subverting signaling pathways that
normally down-regulate critical immune responses.
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The CD4 receptor itself has been shown to transduce signals after stimulation with HIV Envs
leading to apoptosis.121 One of the first studies to show the participation of apoptosis in
CD4+ T cells infected with HIV-1 in vitro was performed by Laurent-Crawford et al.25 This
study demonstrated that apoptosis was initiated in HIV-infected cells prior to cell lysis and
suggested that apoptosis is the direct cause of cell death by HIV infection.25 Also, stable cell
clones expressing Env showed the characteristic features of apoptosis (DNA fragmentation
and nuclear chromosome condensation) and these effects were seen as early as 8 h after
induction.86
In addition to activating signaling by chemokine receptors, Env stimulates the induction of
caspase-3 and caspase-6 in a CD4 receptor-dependent manner.85,122 The activation of these
two caspases is most likely the molecular mechanism responsible for the major apoptotic
activity induced by the HIV envelope, since this activity can be inhibited by use of soluble
CD4 (sCD4).85,122 HIV Env also induces the phosphorylation of focal adhesion kinase (FAK)
and the formation of this complex may contribute to the dysregulation of cellular activation
and trafficking associated with HIV infection. FAK is cleaved in a caspase-3- and caspase-6-
specific pattern and the cleavage of FAK by caspase-3 is associated with the early stages of
apoptosis.85,122 Thus, the activation and subsequent cleavage of phosphorylated FAK may
represent the critical early step in HIV-1 induced apoptosis.
Nef
Several biological activities have been attributed to the Nef protein of HIV, including the down-
regulation of cell surface CD4,123,124 and MHC class I,122,123 enhancement of virion
infectivity,125–127 increased activation of expressing cells,127,128 and enhancement of
apoptosis.129,130 In vitro, several researchers have reported difficulties in establishing stable
cell lines constitutitvely expressing Nef due to Nef toxicity when this protein is expressed in
transfected cell lines.131,132
The activation of apoptosis by Nef has recently been demonstrated by a variety of researchers.
Okada et al133 demonstrated that extracellular Nef induced apoptosis in both lymphoid and
myeloid cells through a Fas-independent pathway. However, a contradictory study indicated
that Nef induced Fas-L expression, which triggered Fas-mediated T cell death. Xu et al134
showed that Nef and the ? chain of the T cell receptor (TCR) were required and sufficient to
upregulate Fas-L in T cells. Also lending support to this hypothesis, Fas-L activation in T cells
by SIV depends on the expression of an intact Nef protein.135 In addition, Nef from a highly
pathogenic form of SIV (smmPBj14) alone can directly cause Fas-L up-regulation.135
Possible intracellular targets, important for Nef-mediated apoptosis, have been identified. Nef
associates with cellular serine/threonine kinases (possibly PAK), as well as src-like tyrosine
kinases (Hck and Lck).136–138 Both of these types of kinases are important in T cell
activation.136–139 Consistent with this observation, Fas-L is expressed following activation of
the TCR leading to the phosphorylation of these kinases and expression is inhibited by cell
treatment with immunosuppressive drugs.139 Ras signaling has also been implicated in tyrosine
kinase activation and hence both the Ras and Lck pathways may contribute to the up-regulation
of Fas-L transcription.140 Therefore, HIV infection may activate tyrosine kinases (via Nef)
that converge in a common activation pathway leading to Fas/Fas-L interaction and the
induction of apoptosis.129 Other HIV-1 gene products, particularly Tat and Env, together with
Nef may act in concert to induce Fas-L and to increase Fas-based cytotoxicity.19,141
Vpu
One of the least understood accessory protein expressed by HIV is Vpu. Two separate functions
have been ascribed to Vpu. One of these functions is the ability of this protein to enhance HIV
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release from infected cells.26,142,143 This property is not restricted just to HIV, since Vpu can
also enhance the release of virus particles generated from other retroviruses. A second function
associated with Vpu is the disruption of Env–CD4 interactions in the endoplasmic
reticulum.26,142 Vpu appears to interact with the cytoplasmic tail of CD4 and targets CD4 to
proteosomes for degradation. These two functions can be segregated to different regions of the
Vpu protein.26,142 The transmembrane region of Vpu is responsible for the increased viral
release and the cytoplasmic tail is needed for CD4 degradation.26,142
Vpu has several structural similarities to the M2 protein of influenza virus.143,144 Both M2 and
Vpu form cation-selective ion channels.145–147 The means by which Vpu ion channel activity
might increase virus release is unknown. However, it is tempting to speculate that the ion
channel properties of Vpu cause cells to be more responsive to apoptotic stimuli. Perturbations
in potassium levels in neurons and decreased potassium levels in T cells directly cause
apoptosis.147–149 Interestingly, both Bcl-2 and Bax also have ion channel properties and may
enhance ion-channel formation.150–152
Vpu has a large effect on the susceptibility of cells to Fas-induced apoptosis. Deletion of Vpu
from the HIV genome increases survival in response to Fas cross-linking in both T cell lines
and freshly isolated PBLs. In addition, an enhanced death rate is observed in cells infected with
clones of HIV expressing Vpu. This enhanced rate correlates with increased Fas-induced cell
death. However, deleting Vpu does not completely eliminate the sensitivity of HIV-1-infected
cells to Fas killing. Most likely, the increase in cell death can be attributed to other viral gene
products including Env and Tat. Interestingly, there is no homologue of Vpu in SIV or HIV-2.
Therefore, the lack of Vpu in these two lentiviruses may help to explain their reduced
pathogenicity compared to HIV-1. Interesting results have been obtained from rhesus
macaques infected with SHIV chimeras (proviruses with an HIV env region contained in an
SIV genomic backbone), which used a Vpu gene containing a mutated start codon
(ACG).153 Several months after infection, these monkeys developed AIDS-like symptoms.
The virus recovered from these animals had a Vpu start codon that had reverted to the wild-
type ATG codon and therefore Vpu was expressed in these animals,153 again demonstrating
that Vpu expression is important for inducing immunodeficiency disease.
Summary
The regulation of apoptosis by HIV has profound implications for both the virus and the
infected host cells. Induction of apoptosis has the potential of significantly influencing virus
load and transmission rates as well as the response by the host immune system to the virus.
HIV encodes a variety of gene products that can induce or inhibit apoptotic pathways (Figure
1). Apoptosis activation in bystander immune cells is the key to the depletion of T lymphocytes
observed in HIV-1 infected patients. In a variety of model systems, viral genes can modulate
apoptosis. Tat, Nef, and Vpu can protect infected cells from apoptotic stimuli. Env, Vpr, Vpu,
and Tat can also induce apoptosis, particularly in non-infected cells. Understanding apoptotic
mechanisms, induced by viral proteins, is important for the development of anti-HIV
treatments. HIV-induced apoptosis may have detrimental effects on prophylactic
administration of anti-viral drugs and vaccines. No vaccine capable of eliciting protective
immunity to HIV infection has been formulated and HIV presents a formidable challenge to
immune surveillance. The induction of apoptosis by HIV gene products, which could be
expressed in a potential vaccine, may have adverse effects on the host. Therefore, a more
thorough comprehension of the modulation of apoptosis by HIV proteins is critical for the
development of an effective HIV vaccine and decreasing disease pathogenesis.
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Figure 1.
Model describing mechanisms of HIV modulation of apoptosis. HIV virions bind to cell surface
CD4 and a coreceptor (primarily CCR5 or CXCR4) via Env initiating fusion with the cell
membrane and releasing the virus-containing capsid into the cell cytoplasm. After reverse
transcription process, the provirus is translocated to the nucleus and integrates into the host
genome. Transcription of viral mRNA leads to the production of viral gene products. (1) Nef
is expressed early in the life cycle and associates with the cell membrane where it interacts
with a variety of proteins including p56lck. Nef interaction with the ? chain of the TCR results
in the up-regulation of Fas-L expression. (2) Fas-L expression can protect infected cells from
cytotoxic T cell lymphocyte (CTL) killing by destroying immune cells expressing Fas. (3) Nef
can down-regulate the expression of cell surface receptors CD4 and MHC class I and (4) protect
the infected cells from recognition by CTLs. (5) Vpu can also prevent the cell surface
expression of CD4 and therefore also protect infected cells from killing by CTLs. (6) In contrast
to Nef and Vpu, Vpr expression can induce apoptosis by the induction of cell arrest at the G2
phase of the cell cycle in HIV-infected cells. (7) Tat is among the first viral gene products to
be expressed after proviral integration. Tat increases the expression of IL-2 (a T cell growth
factor) and Bcl-2 (an anti-apoptotic protein), both of which protect infected cells from the
induction of apoptosis. (8) However, expression of an exogenous, soluble form of Tat (sTat)
induces apoptosis in many bystander cells. Interacting with cell surface receptors on T cells
and macrophages, sTat can induce bystander cells to undergo apoptosis by initiating the
expression of Fas, Fas-L, and TNF-?. In addition, sTat can down-regulate the expression of
Bcl-2. Both TNF-?/TNFRII and Fas/Fas-L interactions can induce apoptosis in T cells by
activation of caspases and the upregulation of Fas and Fas-L expression. (9) Progeny virion
release can also induce apoptosis in bystander cells. The interaction of Env with cell receptors
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initiates CD4 and CXCR4 cell signaling pathways and subsequently activates various caspases
leading to cell death.
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Table 1
HIV gene products involved in modulation of apoptosis
HIV protein Mechanisms of action Effect on apoptosis
Env Signal activation of CD4 Enhancement
Signal activation of chemokine receptor Enhancement
Syncytium formation Enhancement
Nef Activation of Fas-L expression Enhancement
Down-regulation of CD4 and MHC I Inhibition
Tat Signal transduction in Fas-dependent manner Enhancement
Activation of cyclin-dependent kinases Enhancement
Increases in Bcl-2 expression Inhibition
Increases in IL-2 expression Inhibition
Vpr Induction of cell cycle G2 arrest Enhancement
Activation of I?B Inhibition
Vpu Increases in ion channel activity Enhancement
Interactions with Fas Enhancement
Down-regulation of CD4 Inhibition
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